Related Experiment Videos
Impairment of GM-CSF production in myelodysplastic syndromes
1L. e A. Seragnoli Institute of Haematology, University of Bologna, Italy.
Abstract:
In this study we evaluated the production of granulocyte/macrophage-colony stimulating factor (GM-CSF), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) by enriched bone marrow (BM) macrophages in 15 patients affected by myelodysplasia and 20 normal BM donors. The presence of GM-CSF, IL-6 and TNF-alpha in the culture supernatants of BM macrophages was detectable only after stimulation with lipopolysaccharide (LPS), whereas no differences were present in the amount of IL-6 and TNF-alpha between myelodysplastic patients and normal controls, GM-CSF production appeared eight-fold reduced in BM macrophage culture supernatants from myelodysplastic patients with respect to normal controls. After further experiments, we concluded that the impaired release of GM-CSF by BM macrophages could not be due to a different production kinetic in myelodysplastic patients. Moreover, the number of multipotent (CFU-GEMM), granulocyte/macrophage (CFU-GM) and erythroid (BFU-E) progenitors was significantly impaired in myelodysplastic patients. In conclusion, we demonstrated that the production of GM-CSF by purified adherent cells from MDS patients is markedly impaired in spite of the peripheral blood cytopenia. This selective defect in GM-CSF production, along with an intrinsic defect of haematopoietic progenitor cells, might contribute to the impairment of haematopoiesis always observed in myelodysplastic patients.
Insights
Myelodysplastic patients show significantly reduced production of granulocyte/macrophage-colony stimulating factor (GM-CSF) by bone marrow macrophages. This impaired GM-CSF release, alongside defective hematopoietic progenitors, contributes to myelodysplasia.
Area of Science:
- Hematology
- Immunology
- Cell Biology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Impaired hematopoiesis and cytopenias are characteristic of MDS.
- The role of bone marrow macrophages and cytokine production in MDS pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the production of key cytokines, including granulocyte/macrophage-colony stimulating factor (GM-CSF), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), by bone marrow macrophages in patients with MDS.
- To compare cytokine production in MDS patients with healthy controls.
- To assess the impact of impaired cytokine production on hematopoietic progenitor cells in MDS.
Main Methods:
- Enriched bone marrow (BM) macrophages were isolated from 15 MDS patients and 20 healthy BM donors.
- Macrophage cultures were stimulated with lipopolysaccharide (LPS).
- Levels of GM-CSF, IL-6, and TNF-alpha in culture supernatants were measured.
- The number of hematopoietic progenitors (CFU-GEMM, CFU-GM, BFU-E) was assessed.
Main Results:
- GM-CSF production by BM macrophages was approximately eight-fold lower in MDS patients compared to normal controls after LPS stimulation.
- No significant differences in IL-6 and TNF-alpha production were observed between MDS patients and controls.
- The production kinetic of GM-CSF did not differ between the groups.
- MDS patients exhibited a significant reduction in multipotent, granulocyte/macrophase, and erythroid progenitors.
Conclusions:
- Purified bone marrow macrophages from MDS patients demonstrate markedly impaired GM-CSF production, despite peripheral blood cytopenia.
- This selective defect in GM-CSF production, coupled with intrinsic defects in hematopoietic progenitor cells, likely contributes to the impaired hematopoiesis seen in MDS.
- Findings suggest a potential role for macrophage-derived GM-CSF dysregulation in MDS pathogenesis.